Assessment of risk factors of treatment discontinuation among patients on paliperidone palmitate and risperidone microspheres in france, germany and belgium – a retrospective datab... by R. Cai, F. Decuypere, P. Chevalier, A. Wimmer, P. Guillon, S. Pype, A. Godet, V. Timtschenko

“…Additionally, a significantly higher treatment continuation was found for ‘stable’ PP3M patients (81.8%) than ‘stable’ PP1M patients (62.9%). …”
Get full text